Back to Search Start Over

Clinical and toxicity outcomes with 3D based-HDR surface mold brachytherapy in skin cancer.

Authors :
Yadavalli, Purnachandrarao
Pareek, Vibhay
Barthwal, Mansi
Bharat, Rampukar
Mullassery, Shreejesh
Aashita
Patil, Preeti
Sharma, Aman
Sharma, Daya Nand
Mallick, Supriya
Source :
Journal of Cancer Research & Therapeutics. Apr-Jun2024, Vol. 20 Issue 3, p930-934. 5p.
Publication Year :
2024

Abstract

Introduction: Surface mold brachytherapy(SMBT) is an established treatment modality in skin cancer, especially in accessible areas, and has shown comparable outcomes to surgery. We have presented our results for the skin tumor treatment with SMBT treated with high-dose-rate (HDR) brachytherapy in terms of clinical outcomes and toxicity at our institute. Materials and Methods: In this retrospective analysis, 15 patients with skin cancer were treated with customized tube-based SMBT at our institute between January 2019 and July 2021. The patients were treated using HDR-brachytherapy using Iridium-192. The median dose was 40 Gy in 10 fractions. The dosimetric parameters were assessed, and patients were followed up as per the institutional protocol. All patients underwent individualized CT-based planning. Skin toxicity was assessed using the Dermatology Life Quality Index (DLQI). Results: With the majority of the patients being male, the median age was 59 years and the most common site affected was the face (8/15; 53.3%). Among the 15 cases, five were squamous cell carcinoma, nine were basal cell carcinoma, and a single case of sebaceous cell carcinoma. The median depth of invasion was 4 mm, and the median catheter-to-surface distance was 1 mm. The complete response rate among the 10 definitive cases was 90% and partial response in one case. The treatment was well-tolerated with no grade 3-5 toxicities. The median V95% and V90% were 94.8% and 97.1%, respectively. The mean coverage index (C.I.), dose non-uniformity ratio (DNR), and overdose volume index(ODI) were 0.97, 0.13, and 0.05, respectively. After a median follow-up of 12 months, none of the patients had recurrence. On assessment of DLQI, the scores were found to be significant in association with the tumor size and tumor site with scores favoring <2 cm and non-exposed area lesions. Conclusion: SMBT is a safe and effective treatment modality for skin tumors providing excellent response and cosmetic outcomes. It is well-tolerated and a non-invasive option for elderly patients with comorbidities and lesions in inoperable areas. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
09731482
Volume :
20
Issue :
3
Database :
Academic Search Index
Journal :
Journal of Cancer Research & Therapeutics
Publication Type :
Academic Journal
Accession number :
178742302
Full Text :
https://doi.org/10.4103/jcrt.jcrt_2641_22